Department of Theriogenology and Biotechnology, College of Veterinary Medicine, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 08826, Republic of Korea.
LARTBio Inc., 60 Haan-ro, Gwangmyeong-si, Gyeonggi-do, 14322, Republic of Korea.
Sci Rep. 2024 Nov 12;14(1):27750. doi: 10.1038/s41598-024-76937-2.
Gene therapy is a promising method for treating inherited diseases by directly delivering the correct genetic material into patient cells. However, the limited packaging capacity of vectors poses a challenge. Minimizing promoter size is a viable strategy among various approaches to address this issue. This study aims to optimize the bovine myostatin (MSTN) promoter, enhancing its utility in gene therapy applications. We identified the primary driver of activity as the proximal regulatory region. Isolated from the native promoter and termed M243, this 243-bp sequence was assessed for its potential as a ubiquitous promoter. In a variety of cell types, including bovine embryos and embryonic stem cells, the M243 promoter showed consistent expression, highlighting its suitability for applications requiring compact promoters. The isolation of a highly conserved, compact 243-bp sequence serving as a promoter suggests a solution for overcoming the size constraints of AAV vectors, suggesting potential contributions to the field of gene therapy.
基因治疗是一种通过直接将正确的遗传物质递送到患者细胞中来治疗遗传性疾病的有前途的方法。然而,载体的有限包装能力构成了挑战。在各种解决此问题的方法中,最小化启动子大小是一种可行的策略。本研究旨在优化牛肌肉生长抑制素(MSTN)启动子,增强其在基因治疗应用中的实用性。我们确定了活性的主要驱动因素是近端调节区。从天然启动子中分离出来并命名为 M243 的 243 个碱基对序列被评估为其作为普遍启动子的潜力。在包括牛胚胎和胚胎干细胞在内的多种细胞类型中,M243 启动子表现出一致的表达,突出了其在需要紧凑启动子的应用中的适用性。作为启动子的高度保守、紧凑的 243 个碱基对序列的分离为克服 AAV 载体的大小限制提供了一种解决方案,这表明可能对基因治疗领域做出贡献。